Cargando…

Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway

Prostate cancer represents a major concern in human oncology and the phytoalexin resveratrol (RES) inhibits growth and proliferation of prostate cancer cells through the induction of apoptosis. In addition, previous data indicate that in oestrogen-responsive human breast cancer cells, RES induces ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benitez, D A, Pozo-Guisado, E, Clementi, M, Castellón, E, Fernandez-Salguero, P M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359939/ https://www.ncbi.nlm.nih.gov/pubmed/17486135 http://dx.doi.org/10.1038/sj.bjc.6603755

Ejemplares similares

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk
por: Stevens, K N, et al.
Publicado: (2011)

Methylation status of oestrogen receptor-α gene promoter sequences in human ovarian epithelial cell lines
por: O'Doherty, A M, et al.
Publicado: (2002)

Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
por: Merson, S, et al.
Publicado: (2014)

The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor α
por: Wada-Hiraike, O, et al.
Publicado: (2005)

CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk
por: Garcia-Albeniz, Xabier, et al.
Publicado: (2016)

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer
por: Svensson, Charlotte, et al.
Publicado: (2014)

CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites
por: Sood, Deepti, et al.
Publicado: (2017)

Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels
por: Jesser, C, et al.
Publicado: (2008)

Œstrogenic and Androgenic Substances in Pregnancy
por: Hain, A. M.
Publicado: (1938)

hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan
por: Fletcher, G C, et al.
Publicado: (2003)

Oestrogen and androgen receptors in melanoma.
por: Rümke, P., et al.
Publicado: (1980)

Resveratrol inhibits benzo[a]pyrene–DNA adduct formation in human bronchial epithelial cells
por: Berge, G, et al.
Publicado: (2004)

CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia
por: Tayeb, M T, et al.
Publicado: (2003)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer
por: Agalliu, I, et al.
Publicado: (2007)

Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer
por: Julin, B, et al.
Publicado: (2015)

CHEK2 variants associate with hereditary prostate cancer
por: Seppälä, E H, et al.
Publicado: (2003)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Mutation analysis of the MSMB gene in familial prostate cancer
por: Kote-Jarai, Z, et al.
Publicado: (2010)

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours
por: Tanic, M, et al.
Publicado: (2013)

Proceedings: Oestrogen and androgen receptors in human breast cancer.
por: Engelsman, E., et al.
Publicado: (1974)

Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families
por: Ray, A M, et al.
Publicado: (2009)

Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes
por: Mühlbauer, K-R, et al.
Publicado: (2003)

Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
por: Lindmark, F, et al.
Publicado: (2005)

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
por: Pashayan, N, et al.
Publicado: (2011)

Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci
por: Brown, W M, et al.
Publicado: (2004)

Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders
por: Gibson, Douglas A., et al.
Publicado: (2018)

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease
por: Leongamornlert, D, et al.
Publicado: (2014)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

ATM polymorphisms as risk factors for prostate cancer development
por: Angèle, S, et al.
Publicado: (2004)

Phosphoinositide 3-kinase beta controls replication factor C assembly and function
por: Redondo-Muñoz, Javier, et al.
Publicado: (2013)

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer
por: Hart, Steven N, et al.
Publicado: (2016)

Polymorphism of the insulin gene is associated with increased prostate cancer risk
por: Ho, G Y F, et al.
Publicado: (2003)

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
por: Mikropoulos, Christos, et al.
Publicado: (2018)

Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours
por: Reiman, A, et al.
Publicado: (2011)

Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer
por: Chang, B L, et al.
Publicado: (2003)

Rapid progression of prostate cancer in men with a BRCA2 mutation
por: Narod, S A, et al.
Publicado: (2008)

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk
por: Cheng, I, et al.
Publicado: (2007)

The role of coactivators in oestrogen action
por: Brown, M, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_mnfn4v8kj001otkgq6sbbdms8r